Výsledky vyhledávání - "Heinrich Schulte"

Akademický článek

Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection

Autor: Heinrich Schulte-Baukloh, Apostolos Apostolidis, Catarina Weiss, Thorsten Schlomm, Sarah Weinberger, Dirk Höppner, Kathrin Haberecht, Carsten Waskow, Hendrik Borgmann, Jörg Neymeyer, Bernhard Ralla

Publikováno v: Toxins, Vol 16, Iss 11, p 462 (2024)

Background: The onabotulinumtoxinA detrusor injection (OnabotA DI) was approved a decade ago for the treatment of patients with idiopathic overactive bladder (iOAB) or neurogenic detrusor overactivity (nDO) dysfunction who had not been treated succes

Externí odkaz: https://doaj.org/article/30daf8f242d9435cb684d8fc50bd9f9b

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade after Approval: A Single-Blind Study to Evaluate the Reduction in Pain in OnabotulinumtoxinA Detrusor Injection Using Different Injection Needles

Autor: Heinrich Schulte-Baukloh, Catarina Weiss, Thorsten Schlomm, Sarah Weinberger, Hendrik Borgmann, Dirk Höppner, Kathrin Haberecht, Jörg Neymeyer

Publikováno v: Toxins, Vol 16, Iss 9, p 395 (2024)

Overactive bladder (OAB) has a significant impact on the quality of life; thus, it requires treatment that can be adhered to over a long period without undue side effects. The current treatment which uses an anticholinergic or β-3 agonist may fail t

Externí odkaz: https://doaj.org/article/8fee1936605f445e9f6e302eec655fdf

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients—Preliminary Results

Autor: Heinrich Schulte-Baukloh, Catarina Weiß, Sarah Weinberger, Mandy Hubatsch, Thorsten Schlomm, Bernhard Ralla

Publikováno v: Toxins, Vol 15, Iss 1, p 30 (2022)

Introduction: Detrusor injection with onabotulinumtoxin A (OnabotA-DI) is an established therapy for overactive bladder (OAB). Little is known about the exact onset and course of the effect in the days after the injection therapy. By using a new type

Externí odkaz: https://doaj.org/article/9a64158b0206417d9c80605b1df3080d

Zobrazit plný text záznamu

Plný text ve formátu HTML

OnabotuliumtoxinA Detrusorinjektion: Die 'Real World' der Anwender, die 'Real World' der Patienten – Update BOTUROLOGY 2022

Autor: Heinrich Schulte-Baukloh, Dirk Höppner, Mandy Hubatsch, Katharina Mala, Thorsten Schlomm, Sarah Weinberger

Publikováno v: Aktuelle Urologie. 54:55-60

Zusammenfassung Hintergrund OnabotulinumtoxinA (Botox) ist in Deutschland seit 2013 nach Versagen einer anticholinergen Therapie für die Second-line Behandlung der idiopathischen überaktiven Harnblase als Detrusorinjektion (OnabotA-DI) zugelassen.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::792275177a96c9c4f37d2c8082ec562e
https://doi.org/10.1055/a-1924-7517

Zobrazit plný text záznamu

Subjective Outcome after Discontinuation of Botulinum Toxin-A Detrusor Injection for Lower Urinary Tract Disorders: The Majority Suffers!

Autor: Heinrich, Schulte-Baukloh, Özge, Atamen-Grehn, Helmut Heinz, Knispel, Thorsten, Schlomm, Sarah, Weinberger

Publikováno v: Urologia Internationalis. 107:263-272

Introduction: According to the EAU guidelines, botulinum toxin type A (BoNT-A) detrusor injections are one of the last options in the management of overactive bladder before opting for invasive surgery. So far, there have been no studies dedicated ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90736c5260e93afe6ce52d953ee1182a
https://doi.org/10.1159/000525033

Zobrazit plný text záznamu

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice

Autor: Amin Boroujerdi, Elisabeth Farrelly, Anand Patel, María Fernanda Lorenzo-Gómez, Rizwan Hamid, Heinrich Schulte-Baukloh

Publikováno v: International Urogynecology Journal

Introduction and hypothesis In randomized clinical trials onabotulinumtoxinA was demonstrated to be an effective and well-tolerated treatment for overactive bladder (OAB) with urinary incontinence (UI). However, data reporting onabotulinumtoxinA use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c934954f14ab551ab4e65b2fbf5b043
https://doi.org/10.1007/s00192-020-04423-0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání